Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

71 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

dbGaP phs000907 Brain Metastases in Squamous Cell Lung Cancers - Eligibility

- 06-04-24 - 5 Formulieren, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: IG.elig
Principal Investigator: Paul K. Paik, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA MeSH: Squamous Cell Carcinoma,Nonsmall Cell Lung Cancer https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000907 Putative oncogenic pathways in squamous cell lung cancer have been recently characterized, although their biologic repercussions in patients is largely unknown. This study sought to discover potential clinical manifestations of major pathways in squamous cell lung cancer, particularly the PI3K pathway. Two key findings emerged: patients with stage IV squamous cell lung cancer whose tumors harbored upstream PI3K aberrations had significantly worse survival and a higher burden of metastatic disease. In addition, brain metastases were significantly more common in these patients than in others. Paired lung primary/brain metastasis genotyping, including RNA sequencing and whole exome sequencing, uncovered a high degree of genetic heterogeneity between lung/brain pairs, and identified potential regulators of the metastatic process to brain.

pht004695.v1.p1

1 Itemgroep 5 Data-elementen

pht004696.v1.p1

1 Itemgroep 5 Data-elementen

pht004697.v1.p1

1 Itemgroep 6 Data-elementen

pht004698.v1.p1

1 Itemgroep 12 Data-elementen

dbGaP phs000855 Resistance studies in Lung Cancer - pht004553.v1.p1

- 16-03-24 - 5 Formulieren, 1 Itemgroep, 2 Data-elementen, 1 Taal
Itemgroep: pht004553
Principal Investigator: Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA MeSH: Carcinoma,Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000855 The purpose of the study was to compare gene expression profiles from a cohort of crizotinib-resistant ALK-rearranged lung tumors and a cohort of treatment-naive ALK-rearranged lung tumors. Expression profiles were generated by RNA-seq. In parallel, gene expression profiles were obtained from ALK-rearranged lung cancer cell lines in the presence or absence of the ALK inhibitor TAE684. Gene expression profiles were also obtained from ALK-rearranged cells ectopically expressing genes associated with ALK inhibitor resistance that were identified from a functional genetic study.

pht004554.v1.p1

1 Itemgroep 3 Data-elementen

pht004552.v1.p1

1 Itemgroep 3 Data-elementen

Eligibility

1 Itemgroep 1 Data-element

pht004551.v1.p1

1 Itemgroep 2 Data-elementen

dbGaP phs000980 PD-1 Blockade in Non-Small Cell Lung Cancer - Eligibility

- 18-11-23 - 5 Formulieren, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: IG.elig
Principal Investigator: Timothy Chan, MD, PhD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA MeSH: Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000980 Patients with non-small cell lung cancer were treated with pembrolizumab. Their tumors and matched normal blood were sequenced.

pht004961.v1.p1

1 Itemgroep 5 Data-elementen

pht004962.v1.p1

1 Itemgroep 5 Data-elementen

pht004963.v1.p1

1 Itemgroep 11 Data-elementen

pht005053.v1.p1

1 Itemgroep 15 Data-elementen

dbGaP phs000488 Genomic Sequencing of Lung Adenocarcinoma - Eligibility

- 13-12-22 - 5 Formulieren, 1 Itemgroep, 1 Data-element, 1 Taal
Itemgroep: IG.elig
Principal Investigator: Matthew Meyerson, MD, PhD, Broad Institute, Cambridge MA, Dana Farber Cancer Institute, Boston MA, USA MeSH: Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000488 Lung carcinoma is the leading cause of cancer death in the United States and world-wide; lung adenocarcinoma is the most common cause of lung cancer. Pilot studies of lung adenocarcinoma with hybrid-capture based whole exome sequencing will enable us to identify new targets for therapy and improve diagnosis. We will analyze a blend of whole exome and whole genome sequencing data as well as copy number and somatic mutation calls for 200 tumor and matched normal controls. When completed this study will represent the most comprehensive lung adenocarcinoma genome dataset to date.

pht002911.v2.p1

1 Itemgroep 10 Data-elementen

pht002912.v2.p1

1 Itemgroep 5 Data-elementen

pht002909.v2.p1

1 Itemgroep 2 Data-elementen

pht002910.v2.p1

1 Itemgroep 3 Data-elementen

dbGaP phs000299 Genentech Lung Cancer Sequencing - pht001553.v2.p1

- 12-10-22 - 6 Formulieren, 1 Itemgroep, 5 Data-elementen, 1 Taal
Itemgroep: pht001553
Principal Investigator: Zemin Zhang, PhD, Genentech Inc., South San Francisco, CA, USA MeSH: Lung Neoplasms,Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000299 Version 1 Whole genome sequencing was applied to tumor and adjacent normal lung tissue in an individual non-small-cell lung cancer patient. We present an analysis of somatic changes identified throughout the tumor genome, including single-nucleotide variants, copy number variants, and large-scale chromosomal rearrangements. Over 50,000 high-confidence single-nucleotide variants were identified, revealing evidence of substantial smoking-related DNA damage as well as distinct mutational pressures within the tumor resulting in uneven distribution of somatic mutations across the genome. Version 2 Lung cancer is a highly heterogeneous disease in terms of both underlying genetic lesions and response to therapeutic treatments. We performed deep whole genome sequencing and transcriptome sequencing on 19 lung cancer cell lines and 3 lung tumor/normal pairs. Overall, our data show that cell line models exhibit similar mutation spectra to human tumor samples. Smoker and never-smoker cancer samples exhibit distinguishable patterns of mutations. A number of epigenetic regulators are frequently altered by mutations or copy number changes. A systematic survey of splice-site mutations identified over 100 splice site mutations associated with cancer specific aberrant splicing, including mutations in several known cancer-related genes. Differential usages of splice isoforms were also studied. Taken together, these data present a comprehensive genomic landscape of a large number of lung cancer samples and further demonstrate that cancer specific alternative splicing is a widespread phenomenon that has potential utility as therapeutic biomarkers.

pht001881.v2.p1

1 Itemgroep 2 Data-elementen

pht001882.v2.p1

1 Itemgroep 7 Data-elementen

pht001551.v2.p1

1 Itemgroep 5 Data-elementen

pht001552.v2.p1

1 Itemgroep 5 Data-elementen

Eligibility

1 Itemgroep 4 Data-elementen

Eligibility NCT01232452 Non-Small-Cell Lung Carcinoma - Eligibility

- 27-09-21 - 1 Formulier, 2 Itemgroepen, 37 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01232452

Eligibility NCT01085136 Carcinoma, Non-Small-Cell Lung - Eligibility

- 27-09-21 - 1 Formulier, 2 Itemgroepen, 30 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01085136

Eligibility Lung Cancer NCT00955175

- 20-09-21 - 1 Formulier, 1 Itemgroep, 11 Data-elementen, 1 Taal
Itemgroep: Criteria
Hypofractionated 3-Dimensional Radiation Therapy in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer. ICORG 99-09; ODM derived from: https://clinicaltrials.gov/show/NCT00955175

Eligibility NCT00858364 Non-Small Cell Lung Cancer - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 33 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00858364

Lung Cancer NCT01041781 Registration - CALGB-30801 Registration Worksheet Form - 2891095v1.0 - CALGB-30801 Registration Worksheet Form

- 20-09-21 - 1 Formulier, 9 Itemgroepen, 36 Data-elementen, 1 Taal
Itemgroepen: Header Module, Protocol Administration, Patient Demographics/Pre-Treatment Characteristics1, Patient Demographics/Pre-Treatment Characteristics2, Patient Demographics/Pre-Treatment Characteristics3, Certification Of Eligibility, Protocol Design, Companion Study, Registration Information
CALGB-30801 Registration Worksheet Form Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6AF26CA3-DB68-EEE0-E040-BB89AD436D54

E5508 On-Study Form NCT01107626

- 20-09-21 - 1 Formulier, 13 Itemgroepen, 75 Data-elementen, 1 Taal
Itemgroepen: Header Module, Patient demographics, Data amendment, Pre-Treatment Characteristics, Pre-Treatment Characteristics1, Advanced NSCLC Disease Description, Metastatic Site, Medical History, Pre-Registration Hematology/Chemistry, Advanced NSCLC Prior Treatment, NSCLC Brain Metastases, Baseline Abnormalities, Comments
E5508 On-Study Form NCT01107626 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6D435D37-5591-AA13-E040-BB89AD43538D

Lung Cancer NCT00946712 Pre-Study - Southwest Oncology Group S0819 Prestudy Form - 2863901v1.0 - Southwest Oncology Group S0819 Prestudy Form

- 20-09-21 - 1 Formulier, 8 Itemgroepen, 72 Data-elementen, 1 Taal
Itemgroepen: Header Module, PATIENT AND DISEASE DESCRIPTION, PATIENT AND DISEASE DESCRIPTION1, LABORATORY VALUES, LABORATORY VALUES1, ADDITIONAL PRESTUDY DATA, PRIOR TREATMENT RELATED TO THIS CANCER, Comments
Southwest Oncology Group S0819 Prestudy Form Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=684FE956-5AAF-A7DA-E040-BB89AD432A2B

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial